
Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ:FATE) and Century Therapeutics Inc (NASDAQ:IPSC), an analyst at BofA Securities said in a note on Tuesday.
The Biopharma Analyst: Tazeen Ahmad has a Buy rating and $112 price target on Fate shares.
The analyst rates Century a Buy with a $34 price target.